Stockscreener 앱 받기
1.53
0.66%
0.01
시간 외 거래:
1.49
-0.04
-2.61%
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Could Drug Research Partnership Just Shift Quantum Computing's (QUBT) Investment Narrative? - Simply Wall Street
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Form 4 Palisade Bio Inc: Julien E. Capers (Officer) For: 19 October - Investing.com UK
Form 8K INmune Bio Inc For: 21 October By Investing.com - Investing.com South Africa
UK approval could come about six weeks earlier, Inmune Bio (INMB) says of its revised Ebstrocel plan. - Stock Titan
A treatment for children with a skin disease could gain UK approval about six weeks sooner. - Stock Titan
Doctors may be able to request INmune Bio’s experimental cell therapy before local approval. - Stock Titan
Quantum Technology Meets Biotechnology: INmune Bio and Quantum Computing Inc. Team Up to Accelerate Drug Discovery - TheStreet
A quantum-computing company gets its first customer in pharma and biotech: INmune Bio - Stock Titan
Full Transcript: INmune Bio Q2 2026 Earnings Call - Benzinga
TRex Bio, Inc. Common stock (TRXB) company profile and facts - Yahoo Finance UK
TRex Bio, Inc. Common stock (TRXB) stock price, news, quote and history - Yahoo Finance UK
INmune Bio stock heads into Maxim summit before Q3 results - AD HOC NEWS
Quantum Computing Inc. Announces Dirac-3S, Scaling to Nearly 10,000 Variables - Stock Titan
Form 4 INmune Bio Inc For: 23 September - Investing.com India
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com UK
Inmune Bio (INMB) gives director 3-year option grant - Stock Titan
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan
A Sanofi rare-disease leader joins INmune Bio's board for a possible treatment launch. - Stock Titan
INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Inmune Bio stock steadies as investors await next data catalyst - ad-hoc-news.de
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - simplywall.st
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com India
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - Yahoo Finance
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB - Investing.com
INmune (INMB) Financial Results: EPS Comes in Above Forecast on the Day; Post-Earnings: The Stock Gains 1.72% in the Latest ReadingEarnings Analysis - dars.gov.et
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Put Spread Alert - dars.gov.et
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com Nigeria
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - The Globe and Mail
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
44.16%
6.39%
자본화:
|
볼륨(24시간):